<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03180723</url>
  </required_header>
  <id_info>
    <org_study_id>RMPGN</org_study_id>
    <nct_id>NCT03180723</nct_id>
  </id_info>
  <brief_title>Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis</brief_title>
  <official_title>Effect of Rituximab in Treatment of Primary Membranoproliferative Glomerulonephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type I membranoproliferative glomerulonephritis (MPGN) is a relatively uncommon glomerular&#xD;
      disease, constituting 1.8% of renal biopsies performed in Rochester, minnesota, United States&#xD;
      of America, at the Mayo Clinic, between 1993 and 2008. The prognosis of idiopathic Type I&#xD;
      MPGN is relatively poor. Recently, Irish series, slightly more than 50% of patients developed&#xD;
      end stage renal disease after a mean follow up of 14 years . The disease may recur after&#xD;
      renal transplantation . High-dose glucocorticoids have been used to treat this disease in&#xD;
      children but there is no established treatment in adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type I MPGN is associated with a variety of disorders, including hepatitis, especially&#xD;
      hepatitis C, cryoglobulinemia, monoclonal gammopathies, systemic lupus erythematosus, and&#xD;
      bacterial endocarditis or other chronic bacterial infections . Idiopathic Type I MPGN is&#xD;
      rare. Biopsy samples usually stain for C3 and properdin. However, immunoglobulin G is also&#xD;
      present in most cases, especially if the biopsy is performed early in the course of the&#xD;
      disease suggesting antibody production as a possible therapeutic target.&#xD;
&#xD;
      Rituximab is a chimeric murine/human immunoglobulin g1 kappa monoclonal antibody targeting&#xD;
      the cluster of differentiation 20 antigen found on pre-B and mature B lymphocytes, but not on&#xD;
      hematopoietic stem cells, pro-B cells, normal plasma cells or the cells of other normal&#xD;
      tissues. In the United States it was approved by the US Food and Drug Administration in 1997&#xD;
      for non-Hodgkin's lymphoma and was later approved for rheumatoid arthritis. Intravenous&#xD;
      administration of rituximab results in rapid, selective, prolonged B cell depletion.&#xD;
&#xD;
      Anecdotal reports have demonstrated the efficacy of rituximab in treating MPGN secondary to&#xD;
      chronic lymphocytic leukemia. Rituximab has also been shown to be effective in patients with&#xD;
      MPGN related to a monoclonal gammopathy.&#xD;
&#xD;
      In an open label trial with rituximab, six patients with MPGN type I were treated with&#xD;
      rituximab 1000 mg on days 1 and 15 and followed for 1 year. Proteinuria fell in all patients,&#xD;
      at all time points, after rituximab administration. Renal function did not change.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">July 1, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>effect of Rituximab on proteinuria</measure>
    <time_frame>3 months</time_frame>
    <description>measured through urinary protein/ creatinine ratio</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Membranoproliferative Glomerulonephritis</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab is given in 2 doses (1 gm each dose) to a group of15 patients with primary membranoproliferative glomerulonephritis at (0 - after 2 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclosporine is given orally in a dose of 2mg/kg/d for 3 months to another group of patients with primary membranoproliferative glomerulonephritis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Intravenous injection</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporin</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. MPGN either native/renal transplant kidneys with biopsy last 3 years.&#xD;
&#xD;
          2. Age &gt; 18 years.&#xD;
&#xD;
          3. Urinary protein to creatinine ratio &gt; 1.0 in a 24-hour urine collection, despite&#xD;
             angiotensin converting enzyme inhibitor/angiotensin receptor blocker treatment.&#xD;
&#xD;
          4. Patients need to be treated with an ACEI and/or ARB, for at least 3 months prior to&#xD;
             enrollment with the systolic blood pressure &lt; 140 mm Hg for at least 75% of readings.&#xD;
&#xD;
          5. Women must be post-menopausal, surgically sterile or practicing a medically approved&#xD;
             method of contraception.&#xD;
&#xD;
          6. Patients intolerant of ACE inhibitors/ARBs may enter the study without being treated&#xD;
             with these agents.&#xD;
&#xD;
          7. Estimated glomerular filtration rate â‰¥ 25 ml/min per 1.73m^2 in the presence of ACE&#xD;
             inhibitor/ARB therapy. The GFR will be estimated using the 4 variable Modification of&#xD;
             Diet in Renal Disease (MDRD) equation/National Kidney Foundation - Chronic Kidney&#xD;
             Disease (NKF-CKD) guidelines.&#xD;
&#xD;
          8. Adequate liver function.&#xD;
&#xD;
          9. Negative serum pregnancy test (for women of child bearing age).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt;18 years.&#xD;
&#xD;
          2. Secondary MPGN.&#xD;
&#xD;
          3. Presence or suspicion of active infection.&#xD;
&#xD;
          4. Pregnancy.&#xD;
&#xD;
          5. Concomitant malignancies, Major psychiatric disorder. Significant cardiac or pulmonary&#xD;
             disease and any other disease, metabolic dysfunction, physical examination finding, or&#xD;
             clinical laboratory suspicion of a disease/condition that contraindicates the use of&#xD;
             an investigational drug or that may affect the interpretation of the results or render&#xD;
             the patient at high risk from treatment complications.&#xD;
&#xD;
          6. Laboratory Exclusion Criteria (Screening):&#xD;
&#xD;
               -  Hemoglobin:&lt; 8.5 gm/dL&#xD;
&#xD;
               -  Platelets:&lt; 100,000/mm&#xD;
&#xD;
               -  Total bilirubin, Aspartate amino transferase, alkaline phosphatase &gt; 2.5 x Upper&#xD;
                  Limit of Normal unless related to primary disease&#xD;
&#xD;
               -  Positive Hepatitis B or C serology&#xD;
&#xD;
               -  Positive human immunodeficiency virus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Dillon JJ, Hladunewich M, Haley WE, Reich HN, Cattran DC, Fervenza FC. Rituximab therapy for Type I membranoproliferative glomerulonephritis. Clin Nephrol. 2012 Apr;77(4):290-5.</citation>
    <PMID>22445472</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>June 3, 2017</study_first_submitted>
  <study_first_submitted_qc>June 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>June 15, 2017</last_update_submitted>
  <last_update_submitted_qc>June 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed Hassan Farghally</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulonephritis, Membranoproliferative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

